Patents Assigned to Socpra Sciences Sante Et Humaines
  • Publication number: 20230105935
    Abstract: Provided herein are antiviral compounds having the structure of Formula (I) and compositions thereof for use in the treatment of viral infection. In particular, the compounds of Formula (I) are capable of interfering with the export of viral mRNA processing as reflected in the altered accumulation of viral RNA isoforms as well as transport from the nucleus to the cytoplasm. Such compounds show a reduction of HIV, adenovirus and coronavirus infection of cells. The invention provides compounds that may be suitable for the treatment of HIV/AIDS.
    Type: Application
    Filed: December 15, 2020
    Publication date: April 6, 2023
    Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO, SOCIETE DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUEE SOCPRA SCIENCES SANTE ET HUMAINE
    Inventors: David Scott Grierson, Maryam Zamiri, Peter K. Cheung, Benoit Chabot, Alan Walter Cochrane
  • Patent number: 11591366
    Abstract: The present invention provides a macrocyclic compound of formula (I) compositions and kits comprising this compound and their use for preventing or treating pain, or inducing hypothermia or hypotension.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: February 28, 2023
    Assignee: SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C.
    Inventors: Éric Marsault, Marc Sousbie, Richard Leduc, Philippe Sarret, Jean-Michel Longpré, Élie Besserer-Offroy, Rebecca Brouillette, Michael Desgagné
  • Patent number: 11213597
    Abstract: It is provided new chemical entities allowing simultaneous diagnosis and treatment of cancers. More specifically, it is provided a theranostic compound consisting of a stabilized peptide ligand (agonists and antagonists) for the kinin B1 receptors (B1R) conjugated to specific radionuclides (e.g. 64Cu) suitable for dual imaging/radiotherapy applications.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: January 4, 2022
    Assignee: SOCIETE DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUEE SOCPRA SCIENCES SANTE ET HUMAINES S.E.C.
    Inventors: Fernand Gobeil, Brigitte Guerin, Martin Lepage, Robert Sabbagh, David Fortin
  • Patent number: 10988505
    Abstract: The present application relates to a compound of formulae (I), (II) or (III) or a pharmaceutically acceptable salt thereof, methods and uses thereof for treating disorders associated with matriptase activity.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: April 27, 2021
    Assignee: SOCIÉTÉ DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUÉE SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C.
    Inventors: Pierre-Luc Boudreault, Éloïc Colombo, Richard Leduc, Eric Marsault, Baptiste Plancq, Martin Richter
  • Publication number: 20190316211
    Abstract: It is provided a tumor promoting alternative splicing isoform of PACE4, named PACE4-alt CT, analytes specifically binding to PACE4-alt CT, such as antibodies, and use of same for detecting a cancer, such as prostate cancer. It is also provided a method treating a cancer in a patient comprising administering an inhibitor of PACE4-altCT to a patient in need thereof and a kit comprising an analyte specific reagent specifically binding to PACE4-altCT for detecting a cancer.
    Type: Application
    Filed: November 29, 2017
    Publication date: October 17, 2019
    Applicant: SOCIETE DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUEE SOCPRA SCIENCES SANTE ET HUMAINE
    Inventors: Robert DAY, Frédéric COUTURE, Robert SABBAGH
  • Patent number: 10208308
    Abstract: The present invention provides matriptase inhibitors and compositions for treating and preventing orthomyxovirus infections such as flue infections. The present invention also provides novel compounds, compositions, methods of use, uses and kits thereof for inhibiting matriptase. Such compounds are useful for treating and prevention orthomyxovirus infections, such as flu infections, and for inhibiting tumor growth, progression and/or metastasis.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: February 19, 2019
    Assignee: Socpra Sciences Sante Et Humaines S.E.C.
    Inventors: Martin Richter, Richard Leduc, Eloic Colombo, Eric Marsault
  • Patent number: 9809621
    Abstract: It is provided PACE4 inhibitors and their uses for treating infection, cancer. Particularly, it is provided a method or use for the treatment of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the PACE4 inhibitors or the composition disclosed.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: November 7, 2017
    Assignee: SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C.
    Inventors: Robert Day, Witold A. Neugebauer, Yves Dory
  • Patent number: 9752149
    Abstract: The present invention provides matriptase inhibitors and compositions for treating and preventing orthomyxovirus infections such as flu infections. The present invention also provides novel compounds, compositions, methods of use, uses and kits thereof for inhibiting matriptase. Such compounds are useful for treating and preventing orthomyxovirus infections, such as flu infections, and for inhibiting tumor growth, progression and/or metastasis.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: September 5, 2017
    Assignee: SOCPRA SCIENCES SANTE ET HUMAINES S.E.C.
    Inventors: Martin Richter, Richard Leduc, Eloic Colombo, Eric Marsault
  • Patent number: 9573974
    Abstract: Disclosed herein are PACE4 inhibitors, compositions comprising PACE4 inhibitors and their uses thereof for lowering PACE4 activity, reducing cell proliferation, reducing tumor growth, reducing metastasis formation, preventing and/or treating cancer. Also provided are methods for lowering PACE4 activity, reducing the proliferation of a cell, reducing tumor growth and/or treating and preventing cancer. Methods for screening PACE4 inhibitors and cell proliferation inhibitors are further provided.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: February 21, 2017
    Assignee: LA SOCIETE DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUEE SOCPRA-SCIENCES SANTE ET HUMAINES S.E.C.
    Inventors: Robert Day, Martin Fugére, Witold A. Neugebauer
  • Publication number: 20150141324
    Abstract: It is provided furin inhibitors and their uses for treating pathogen infection. Particularly, it is provided a method or use for the treatment of a pathogen infection, in a subject, comprising administering to the subject a therapeutically effective amount of the furin inhibitors or the composition disclosed, thereby preventing or treating pathogen infection, in the subject.
    Type: Application
    Filed: August 31, 2012
    Publication date: May 21, 2015
    Applicant: SOCPRA SCIENCES SANTE ET HUMAINES S.E.C.
    Inventors: Robert Day, Witold A. Neugebauer, Yves Dory
  • Patent number: 8884181
    Abstract: The present disclosure relates to a method and a system for generating low-energy electrons in a biological material. The biological material is held in position by a support. Laser beam pulses are directed by a focusing mechanism toward a region of interest within the biological material. This generates filaments of low-energy electrons within the region of interest. The method and system may be used for radiotherapy, radiochemistry, sterilization, nanoparticle coating, nanoparticle generation, and like uses.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: November 11, 2014
    Assignee: SOCPRA-Sciences Sante et Humaines S.E.C.
    Inventors: Daniel Houde, Ridthee Meesat, Jean-François Allard, Tiberius Brastaviceanu
  • Publication number: 20140206622
    Abstract: It is provided PACE4 inhibitors and their uses for treating infection, cancer. Particularly, it is provided a method or use for the treatment of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the PACE4 inhibitors or the composition disclosed.
    Type: Application
    Filed: August 30, 2012
    Publication date: July 24, 2014
    Applicant: SOCPRA SCIENCES SANTE ET HUMAINES S.E.C.
    Inventors: Robert Day, Witold A. Neugebauer, Yves Dory
  • Publication number: 20140086936
    Abstract: The present invention provides matriptase inhibitors and compositions for treating and preventing orthomyxovirus infections such as flu infections. The present invention also provides novel compounds, compositions, methods of use, uses and kits thereof for inhibiting matriptase. Such compounds are useful for treating and preventing orthomyxovirus infections, such as flu infections, and for inhibiting tumor growth, progression and/or metastasis.
    Type: Application
    Filed: May 28, 2012
    Publication date: March 27, 2014
    Applicant: SOCPRA SCIENCES SANTE ET HUMAINES S.E.C.
    Inventors: Martin Richter, Richard Leduc, Eloic Colombo, Eric Marsault
  • Patent number: 8546346
    Abstract: The present invention relates to a method of modulating splice site selection, splicing and alternative, the method comprising the step of hybridizing an oligonucleotide-protein conjugate to a target pre-mRNA molecule in a cell or cell extract, wherein the oligonucleotide-protein conjugate comprises an oligonucleotide moiety which comprises at least two distinct sequence elements: (i) a nucleic acid sequence that is complementary to a specific region upstream of the splice site in the target pre-mRNA molecule; and (ii) an extension containing a protein binding site sequence element for covalently binding a protein; wherein the protein moiety comprises a protein capable of modulating splicing of the splice site upon binding with the protein binding site.
    Type: Grant
    Filed: November 14, 2008
    Date of Patent: October 1, 2013
    Assignee: La Societe de Commercialisation des Produits de la Recherche Appliquee Socpra-Sciences Sante et Humaines S.E.C.
    Inventors: Benoit Chabot, Jonathan Villemaire, Sherif Abou Elela, Faiz-ul Hassan Nasim
  • Publication number: 20120290519
    Abstract: The present disclosure relates to a method and an apparatus for identifying line-of-responses (LOR) of photons. A radiation detection machine measures the photons. LOR identification errors are then mitigated using pattern recognition of the measurements. In some embodiments, the photons may comprise positron annihilation photons, each position annihilation photon being associated with one or more scattered photons. In yet some embodiments, pattern recognition may be implemented in a neural network.
    Type: Application
    Filed: October 28, 2011
    Publication date: November 15, 2012
    Applicant: SOCPRA SCIENCES SANTE ET HUMAINES S.E.C
    Inventors: Rejean Fontaine, Jean-Baptiste Michaud, Charles-Antoine Brunet, Roger Lecomte
  • Patent number: 8262997
    Abstract: A blood counting device comprises a capillary conduit for drawing from a subject in which a radiotracer has previously been injected a quantity of blood in the micro-liter range to produce in the capillary conduit a flow of blood from which beta radiation is emitted. At least one direct beta radiation detector is placed closely adjacent to the capillary conduit. The direct beta radiation detector consists of a semiconductor photodiode which detects the beta radiation from the flow of blood when directly hit by this beta radiation.
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: September 11, 2012
    Assignee: Société de Commercialisation des Produits de la Recherche Appliquée-Socpra Sciences Sante et Humaines S.E.C.
    Inventors: Laurence Convert, Jules Cadorette, David Lapointe, Roger Lecomte
  • Publication number: 20120122113
    Abstract: The present invention relates to the identification of secreted protein isoforms specific in ovarian cancer and methods for diagnosis or prognosis of ovarian cancer in a subject by detecting the secreted protein isoforms.
    Type: Application
    Filed: April 14, 2010
    Publication date: May 17, 2012
    Applicant: SOCPRA SCIENCES SANTE ET HUMAINES S.E.C.
    Inventors: Panagiotis Prions, Julian Venables, Benoit Chabot, Sherif Abou Elela
  • Publication number: 20120093918
    Abstract: A combination of an anti-cancer agent and a metal radiosensitizer potentiates the radiotherapy of cancer. Said anti-cancer agent is preferably cisplatin while the metal radiosensitizer is preferably gold nanoparticles. Both the anti-cancer agent and the metal radiosensitizer bind to DNA and potentiate the radiotherapy of cancer by synergistically increases the amount of double strand breaks induced by the radiation. The anti-cancer agent and the metal radiosensitizer may be encapsulated in liposomes.
    Type: Application
    Filed: April 26, 2010
    Publication date: April 19, 2012
    Applicant: SOCPRA - SCIENCES SANTE ET HUMAINES
    Inventors: Léon Sanche, Gabriel Charest
  • Patent number: 8076453
    Abstract: The present invention provides for novel kinin B1 receptors peptide agonists of formula (I) having very good to excellent affinities and selectivity for the B1 receptor, in vitro and in vivo increased resistance to enzymatic degradation, superior pharmacokinetic properties to those of naturally occurring agents, capacity to significantly enhance delivery of chemotherapeutic substances across the blood brain barrier and within peripheral tissues for the treatment of tumors, capacity to protect and restore kidney, heart, brain and other organ functions, when given alone or in combination with other therapies in the treatment of hypertension, diabetes and other cardiovascular diseases particularly, but not limited to, atherosclerosis and arteriosclerosis. Formula (I): aay-aax-aa0-aa1-aa2-aa3-aa4-aa5-Ser6-Pro7-D-Phe8-X.
    Type: Grant
    Filed: May 31, 2006
    Date of Patent: December 13, 2011
    Assignee: Societe De Commercialisation Des Produits De La Recheche Appliquee-Socpra-Science Sante Et Humaines S.E.C.
    Inventors: Fernand Gobeil, Jr., Witold A. Neugebauer, Domenico Regoli, David Fortin
  • Patent number: 8053553
    Abstract: Disclosed are compositions and methods for preventing or reducing harm resulting from pathogen infection. For example, disclosed are peptides that inhibit the processing of toxins normally cleaved by proprotein convertase enzymes.
    Type: Grant
    Filed: May 5, 2008
    Date of Patent: November 8, 2011
    Assignees: Socpra Sciences Sante Et Humaines, Illumina, Inc., Sanford-Burnham Medical Research Institute
    Inventors: Alex Strongin, Michal Lebl, Robert Day